SCHEMBL30366333

SCHEMBL30366333

CC(C)(C)OC(=O)N1CC[C@@H](c2ccc(Cl)cn2)[C@H](CO)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
USP2 O75604 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SCN9A Q15858 1/20 0.42
USP30 Q70CQ3 2/20 0.42
STS P08842 1/20 0.42
TRPV3 Q8NET8 1/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NR1D1 P20393 2/20 0.41
NR3C1 P04150 1/20 0.41
FAAH O00519 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30899632 1.00 PDE4B (0.43) PDE4BMEN1KMT2ANPSR1USP2
SCHEMBL30366151 0.87 MEN1 (0.45) MEN1KMT2ANPSR1USP2HPGD
SCHEMBL30899631 0.87 MEN1 (0.45) MEN1KMT2ANPSR1USP2HPGD
SCHEMBL30366202 0.84 MEN1 (0.46) PDE4BMEN1KMT2ANPSR1USP2
SCHEMBL30366230 0.84 MEN1 (0.46) PDE4BMEN1KMT2ANPSR1USP2
SCHEMBL16141287 0.84 PDE4B (0.51) PDE4BMEN1KMT2ASCN9ASTS
SCHEMBL14921544 0.84 PDE4B (0.51) PDE4BMEN1KMT2ASCN9ASTS
SCHEMBL16141288 0.84 PDE4B (0.51) PDE4BMEN1KMT2ASCN9ASTS
SCHEMBL14921543 0.84 PDE4B (0.51) PDE4BMEN1KMT2ASCN9ASTS
SCHEMBL14934477 0.84 PDE4B (0.51) PDE4BMEN1KMT2ASCN9ASTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360126-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2024-10-31 US disclosed
EP-4405051-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2024-07-31 EP disclosed
WO-2023046806-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360126-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE SSB, TPMT, KCNB2 PDE4B 283/4885MEN1 256/4885KMT2A 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.